Karuppiah Kannan on the Past and Future of Myeloma Treatment

Karuppiah Kannan, associate director at Takeda Pharmaceuticals, talks about the progress made in treating myeloma and where the field is going in the future.

About a decade ago, Kannan says that a myeloma diagnosis was like a death sentence, with low five- and ten-year survival rates. Now, advances in medicine are allowing people with the disease to live longer, more normal lives, but work still needs to be done to find a cure.